Enjoy and happy reading!
Welcome to the fall edition of Oncology and Hematology Review (US), which features a wide variety of articles covering topics of interest to oncologists and hematologists. Our expert interviews discuss the PhosphoSynVax™ vaccine platform, new research on the benefits of PARP inhibitors in a broader range of breast cancer patients, and immune checkpoint inhibitors for metastatic urothelial cancer. The journal also covers technical advances in targeted therapy for cholangiocarcinoma, cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis related to gastrointestinal malignancies. Finally, Williams et al. review recent progress in molecular testing for multiple myeloma and the mutation-targeted therapies that are emerging as a result of molecular diagnostic panels.
FOREWORD – ONCOLOGY & HEMATOLOGY (US) – VOLUME 15 ISSUE 2 – FALL 2019
Welcome to the fall edition of Oncology and Hematology Review (US), which features a wide variety of articles covering topics of interest to oncologists and hematologists, as well as the wider medical community. We begin with some expert interviews, which provide a snapshot of some of the hottest topics in oncology. In the first, Paisley Myers […]
Neoantigen Vaccine Delivery for Personalized Anticancer Immunotherapy – the PSV™ Platform
Q. What are phosphopeptide tumor targets and why are they good candidates for vaccine and cell therapy development? PTTs are a novel class of neoantigen. They are portions of aberrantly phosphorylated proteins that are presented at the cell surface to the immune system in the context of human leukocyte antigen (HLA) class I molecules. These […]
PARP Inhibitors may be Beneficial in a Broader Range of Patients
Q. What is the role of PARP-1 in the pathogenesis of cancer? PARP-1 is a protein that resides in the cell nucleus where it plays a role in most, if not all, nuclear functions (e.g. DNA repair, transcription, RNA processing, RNA ribosomal transcription). PARP-1 uses these pathways to assist the cancer cell in its uncontrolled […]
Immune Checkpoint Inhibitors and Novel Agents in the Treatment of Metastatic Urothelial Cancer—Current Status and Future Perspectives
Advanced (locally advanced/unresectable or metastatic) urothelial cancer (UC) is an incurable disease with a poor prognosis.1 Platinum-based chemotherapy is the first-line treatment for most patients and, until recently, patients with advanced UC that has progressed after platinum-based chemotherapy had limited treatment options.2 In recent years, improved understanding of molecular mechanisms underlying the pathogenesis of UC has enabled […]
Emerging Targeted and Immunotherapies in Cholangiocarcinoma
Cholangiocarcinoma is an epithelial malignancy of the biliary system characterized by cholangiocyte differentiation, and its incidence is on the rise. Currently, cholangiocarcinomas are classified by their anatomical location in the biliary system as intrahepatic cholangiocarcinoma, distal cholangiocarcinoma, or hilar cholangiocarcinoma. Since 2010, the standard of care in all advanced, inoperable biliary tract cancers has been combination […]
Understanding Survival Disparities in Gastric Cancer
Gastric cancer was the fifth most common cancer in 2018 with over one million new cases, 55% of which occurred in developed countries.1,2 Mortality remains high and gastric cancer is the third leading cause of cancer-related death in the world.1 Despite decreasing trends in incidence and death worldwide, high rates of gastric cancer remain throughout […]
Hypothermic Intraperitoneal Chemotherapy for Gastrointestinal Malignancies—A Relicof the Past or Useful Tool for Today?
Peritoneal carcinomatosis, defined as tumor dissemination in the peritoneal cavity, is a common manifestation of gastrointestinal malignancies. However, isolated peritoneal metastases (IPM) are relatively rare, though appendiceal tumors and peritoneal mesothelioma have a propensity to involve only the peritoneum. Cytoreductive surgery including hyperthermic intraperitoneal chemotherapy (HIPEC), are now considered standard treatment for appendiceal tumors with […]
Genetic Segmentation and Targeted Therapeutics for Multiple Myeloma
An ever-expanding understanding of the biological basis for multiple myeloma (MM) combined with a widening array of effective therapies has dramatically improved outcomes for patients and has provided new opportunities for disease segmentation and targeted therapeutics.1 While this progress is most welcome, it has created unique challenges for clinicians because of the spatial and temporal heterogeneity, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!